AttendMe Owl Logo
AttendMe
Evidence Evolution
Allergy & ImmunologyAllergy & Immunology

How This Evidence Evolved

Penicillin Allergy Delabeling

From Lifetime Avoidance to Safe Rechallenge

1.2

Timeline

Signal

Early observations and pilot data that first suggested a new direction

Penicillin allergy is commonly recorded at hospital admission but often inaccurate. PALACE notes that fewer than 5% of labeled patients are truly allergic. Label-associated harms differ across cohorts: a UK study reported adjusted HRs of 1.69 for MRSA and 1.26 for C. difficile; a US inpatient cohort reported 23.4% more C. difficile, 14.1% more MRSA, 30.1% more VRE and 0.59 additional hospital days. These are observational associations, not proof that every labeled patient can safely receive penicillin.
Proof

Landmark RCTs and pivotal trials that established the evidence base

Penicillin skin testing emerged as a tool to guide rechallenge: in a 2019 randomized trial, all 70 low-risk patients with a negative skin test tolerated an amoxicillin challenge. The same trial found that a direct 2-step amoxicillin challenge without skin testing was negative in 76 of 79 patients (96.2%), with only minor reactions. The Iammatteo 2019 study showed that placebo-controlled graded amoxicillin challenges without prior skin testing may be safe for patients aged 7 or older with non-life-threatening reactions: only 4 of 155 (2.6%) had mild allergic reactions, simplifying the delabeling process. Skin-test sensitivity also wanes: in a 1999 follow-up, only 12 of 31 patients with positive penicillin skin tests were still positive after 5 years.
The journal of allergy and clinical immunology. In practice 2019Landmark

Safety of direct oral amoxicillin challenge

The journal of allergy and clinical immunology. In practiceProspective randomized controlled trial (159 randomized; 185 consented overall)N=159
Trubiano Delabeling2018

Oral challenge safety in low-risk cancer patients

Open forum infectious diseasesMulticenter pilot oral penicillin challenge program in cancer patients
Iammatteo 20192019

Allergy: 4/155 (2.6%, 95% CI 1.0–6.5%), all mild challenge reactions, vs 14/170 (8.2%) historical patients: 11 positive skin tests and 3 challenge reactions

J Allergy Clin Immunol PractProspective single-blind clinical trial with historical controls; patients aged 7 or older with historical non-life-threatening reactions to penicillin; placebo, then 2-step graded amoxicillin challengeN=155
Blanca 19991999

Positive skin test at 5 years: group A 12 of 31 vs group B 0 of 24 (log-rank 12.8)

J Allergy Clin ImmunolFollow-up of penicillin-allergic patients with positive skin tests, retested at 1, 3 and 5 years (group A n = 31; group B, selective amoxicillin responders, n = 24)
Macy 20142014

Hospital use and infections, penicillin 'allergy' vs matched controls: 0.59 more hospital days (95% CI 0.47-0.71); 23.4% more C difficile, 14.1% more MRSA, 30.1% more VRE

J Allergy Clin ImmunolRetrospective matched cohort of hospitalized patients with a penicillin 'allergy' label, Kaiser Foundation hospitals
Blumenthal 20182018

MRSA and C difficile over mean 6.0 years: penicillin allergy vs comparators (adjusted HR 1.69, 95% CI 1.51-1.90 for MRSA; 1.26, 1.12-1.40 for C difficile)

BMJPopulation-based matched cohort, UK general practice 1995-2015 (64,141 with penicillin allergy, 237,258 matched comparators); mean follow-up 6.0 yearsN=301,399
Extension

Follow-up studies, subgroup analyses, and real-world validation

The PALACE trial (2023) tested a clinical decision rule: 382 adults with a PEN-FAST score below 3, at 6 centers in North America and Australia, were randomized to direct oral penicillin challenge or skin testing followed by challenge. A positive challenge occurred in 1 patient (0.5%) in each arm (risk difference 0.0084 percentage points, 90% CI -1.22 to 1.24), within the 5-point noninferiority margin, with no serious adverse events. Electronic algorithms further scaled the approach: in a 2020 pediatric study, an electronic algorithm identified 61 of 95 children deemed not allergic as low risk, with no false negatives and without allergist assessment or skin testing.
Now

Current standard of care and ongoing research directions

Delabeling strategies need careful patient selection. PALACE found direct oral challenge noninferior to skin testing followed by challenge in adults with PEN-FAST <3, with no serious adverse events. These results support further implementation work in defined populations. Questions include pharmacist/nurse-led delivery, patient-facing tools and whether basophil activation or drug-specific IgE tests can safely change challenge requirements.

Landmark Trials in This Story

Surgical infections 2013

Clinical practice guidelines for antimicrobial prophylaxis in surgery

Guideline on surgical antimicrobial prophylaxis

Surgical infectionsClinical practice guideline
J Allergy Clin Immunol 2015

Patients with positive skin test results to penicillin should not undergo penicillin or amoxicillin challenge

Letter on challenges after positive penicillin skin tests

J Allergy Clin ImmunolLetter
The journal of allergy and clinical immunology. In practice 2019Landmark

Comparing Direct Challenge to Penicillin Skin Testing for the Outpatient Evaluation of Penicillin Allergy: A Randomized Controlled Trial

Safety of direct oral amoxicillin challenge

The journal of allergy and clinical immunology. In practiceProspective randomized controlled trial (159 randomized; 185 consented overall)N=159
Trubiano Delabeling2018

The Safety and Efficacy of an Oral Penicillin Challenge Program in Cancer Patients: A Multicenter Pilot Study

Oral challenge safety in low-risk cancer patients

Open forum infectious diseasesMulticenter pilot oral penicillin challenge program in cancer patients
Iammatteo 20192019

Safety and Outcomes of Oral Graded Challenges to Amoxicillin without Prior Skin Testing.

Allergy: 4/155 (2.6%, 95% CI 1.0–6.5%), all mild challenge reactions, vs 14/170 (8.2%) historical patients: 11 positive skin tests and 3 challenge reactions

J Allergy Clin Immunol PractProspective single-blind clinical trial with historical controls; patients aged 7 or older with historical non-life-threatening reactions to penicillin; placebo, then 2-step graded amoxicillin challengeN=155
Blanca 19991999

Natural evolution of skin test sensitivity in patients allergic to beta-lactam antibiotics.

Positive skin test at 5 years: group A 12 of 31 vs group B 0 of 24 (log-rank 12.8)

J Allergy Clin ImmunolFollow-up of penicillin-allergic patients with positive skin tests, retested at 1, 3 and 5 years (group A n = 31; group B, selective amoxicillin responders, n = 24)
Macy 20142014

Health care use and serious infection prevalence associated with penicillin "allergy" in hospitalized patients: A cohort study.

Hospital use and infections, penicillin 'allergy' vs matched controls: 0.59 more hospital days (95% CI 0.47-0.71); 23.4% more C difficile, 14.1% more MRSA, 30.1% more VRE

J Allergy Clin ImmunolRetrospective matched cohort of hospitalized patients with a penicillin 'allergy' label, Kaiser Foundation hospitals
Blumenthal 20182018

Risk of meticillin resistant Staphylococcus aureus and Clostridium difficile in patients with a documented penicillin allergy: population based matched cohort study.

MRSA and C difficile over mean 6.0 years: penicillin allergy vs comparators (adjusted HR 1.69, 95% CI 1.51-1.90 for MRSA; 1.26, 1.12-1.40 for C difficile)

BMJPopulation-based matched cohort, UK general practice 1995-2015 (64,141 with penicillin allergy, 237,258 matched comparators); mean follow-up 6.0 yearsN=301,399
Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 2020

First pediatric electronic algorithm to stratify risk of penicillin allergy

Pediatric electronic allergy-risk classification compared with allergist assessment

Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical ImmunologyEvaluation of a pediatric electronic allergy-risk algorithm against allergist assessment
PALACE2023

Efficacy of a Clinical Decision Rule to Enable Direct Oral Challenge in Patients With Low-Risk Penicillin Allergy: The PALACE Randomized Clinical Trial.

Positive immune-mediated oral challenge within 1 hour: direct challenge 1 of 187 (0.5%) vs skin test then challenge 1 of 190 (0.5%) (RD 0.0084 pp, 90% CI -1.22 to 1.24; noninferiority margin 5 pp)

JAMA Intern MedOpen-label, multicenter, international noninferiority RCT (3 sites in North America, 3 in Australia); adults with a PEN-FAST score below 3N=382

Explore the evidence yourself

Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.

Related Evidence

Frequently Asked Questions

What percentage of patients labeled penicillin-allergic are truly allergic?+
A small minority. Up to 94-97% of children labeled beta-lactam allergic are found not allergic by an allergist; in PALACE, 1 of 187 low-risk adults (0.5%) had a positive direct challenge. Skin-test sensitivity can wane: in a 1999 study, 12 of 31 skin-test-positive patients were still positive at 5 years.
Is direct oral challenge without skin testing safe?+
The 2019 RCT enrolled patients aged 5 years or older with cutaneous-only or unknown reactions: over 1 year previously for ages 5–17, over 10 years for adults. Direct amoxicillin challenge was negative in 76 of 79 patients (96.2%); positive reactions were minor.
Why does penicillin allergy mislabeling matter clinically?+
Patients with a penicillin allergy label receive more beta-lactam alternatives. In a UK cohort, the label was linked to more MRSA (HR 1.69, 95% CI 1.51-1.90) and C. difficile (HR 1.26, 1.12-1.40). In a US inpatient cohort, labeled patients had 23.4% more C. difficile, 14.1% more MRSA and 30.1% more VRE infections and 0.59 more hospital days.

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. Clinical decisions should always be based on individual patient assessment, local guidelines, and professional judgement.

All data sourced from published, peer-reviewed articles and clinical practice guidelines.

Claims checked against cited sources: 10 November 2026